Tempest Therapeutics, Inc.'s (NASDAQ:TPST) largest shareholders are private equity firms who were rewarded as market cap surged US$127m last week

Key Insights
Significant control over Tempest Therapeutics by private equity firms implies that the general public has more power to influence management and governance-related decisions